1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
Drugs For Benign Prostatic hypertrophy Global Market Report 2021: COVID 19 Impact and Recovery to 2030

Drugs For Benign Prostatic hypertrophy Global Market Report 2021: COVID 19 Impact and Recovery to 2030

  • April 2021
  • 175 pages
  • ID: 6067916
  • Format: PDF
  • The Business Research Company

Summary

Table of Contents

Major players in the drugs for benign prostatic hypertrophy market are Roche Ltd, Hologic, QIAGEN, Abbott, and Danaher Corporation.

The global drugs for benign prostatic hypertrophy market is expected to grow from $4.15 billion in 2020 to $4.79 billion in 2021 at a compound annual growth rate (CAGR) of 15.4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $6.3 billion in 2025 at a CAGR of 7.1%.

The drugs for benign prostatic hypertrophy market consists of sales of benign prostatic hypertrophy drugs to treat enlarged prostate glands. Benign Prostatic Hypertrophy is commonly seen in men older than age 50.

The rising male geriatric population globally is driving the market for Benign Prostatic Hypertrophy drugs as the condition is commonly seen in men aged over 50 years. According to the United Nations’ 2019 World Population Ageing Report, the number of people aged 65 years or above was 703 million in 2019 and is expected to double to around 1.5 billion by 2050. According to the National Institute of Health(NIH), Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years.

Increasing adoption of minimally invasive surgeries due to advancements in technology is restraining the growth of Benign Prostatic Hyperplasia drugs market.Minimally invasive surgeries cause less pain and are generally conducted on an outpatient basis.

This eliminates the need to consume Benign Prostatic Hyperplasia drugs, acting as a restraint on the market. Some of the minimally invasive surgeries used to treat Benign Prostatic Hyperplasia include laparoscopic prostatectomy, transurethral microwave thermotherapy (TUMT) and transurethral needle ablation (TUNA).

Combination drugs are increasingly being used in the treatment of Benign Prostatic Hypertrophy as they are more effective and help prevent disease progression.A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form.

These drugs reduce the development of drug resistance, have fewer side effects and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of Benign Prostatic Hypertrophy.

Benign prostatic hypertrophy drugs manufacturers globally are regulated by various regulatory bodies.For instance, in the European Union, the EU legislation authorizes medicines based on quality, safety, and efficacy.

Companies are mandated to submit compliance documentation for suitable quality before applying for authorization. Manufacturers are required to demonstrate safety and efficacy of drugs using clinical trials data which will be assessed by competent authorities before authorizing for sale.

Major players in the market are Allergan PLC, Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC
Molecular Diagnostics Devices And Equipment

The global molecular diagnostics devices and equipment market is expected to grow from $7 billion in 2019 to $18 billion in 2020 at a compound annual growth rate (CAGR) of 157.2%. The growth of this market is mainly due to the increased diagnostic testing in laboratories, hospitals, and other testing sites across various country to detect the pandemic COVID-19 virus. The need for rapid diagnostic testing such as molecular and RT PCR based testing to identify people infected by coronavirus is driving the in-vitro diagnostics market. The market is then expected to grow at a CAGR of 8.5% from 2021 and reach $14.4 billion in 2023.

The molecular diagnostics devices (or) equipment market consists of sales of molecular diagnostics devices and related services.Molecular diagnostics devices are used to diagnose infectious diseases and perform screening by detecting specific sequences in DNA or RNA at molecular level.

It helps doctors to prescribe more accurate therapeutic interventions in the early stages of a disease. This market is segmented into instruments, reagents and consumables.

In March 2019, Abbott received a CE mark for its Alinity m molecular diagnostic testing machine. This would allow it to sell the product across Europe.

The major players in the molecular diagnostic industry are focusing on developing automated solutions for devices and equipment’s used for molecular diagnostic processes.Automation of the process will help to enhance productivity and consistency of the whole diagnostic process.

Computerisation of the diagnostic process gives reliable and efficient test results that manual testing by various experts does not.The major players of the industry are using nanotechnology based Oral Fluid Nano Sensor Test (OFNASET).

The test uses a microfluidic-based nano sensor for the detection of oral cancer biomarkers in saliva.In order to keep up with the trend of automation and accuracy, Roche, created cobas connection modules (CCM) to improve scalability and sample-flow efficiency by allowing samples to automatically move between different systems and instruments.

Thus, creating a fully automated work flow.

The Molecular Diagnostic Devices And Equipment market has been geographically segmented into North America, Western Europe, APAC, Eastern Europe, South America and Middle East & Africa. The North American Market is the largest market for Molecular Diagnostic Devices And Equipment and is expected to continue to do so during the forecast period

The growth in molecular diagnostic devices and equipment market is attributed to factors such as rapid rise in various bacterial and viral epidemics.The increase in the spread of diseases increases the demand for early and improved diagnostic methods.

In order to improve the technology to enable early diagnosis of such diseases, Government and different organization’s extend their financial support towards the major key players of the industry. For example, according to the reports from Centres for Disease Control and Prevention (CDC) US, as on March 2019, 72 Zika virus disease cases were reported in U.S state and 148 Zika virus disease cases reported in US Territories. Thus, the rise of such chronic diseases serves as a prime driver for the players in the industry to develop more accurate and sophisticated diagnostic devices and equipment’s. Following the increase in demand of early diagnosis of Zika virus, Co-Diagnostics, Inc. in February 2019 launched its first multi-disease molecular diagnostic test for dengue, chikungunya and Zika.

The regulatory process involving approval of molecular diagnostic tests is often slow.The lack of clear definition coupled with constant changes in the regulations is a challenge for companies developing these kits.

In the developing nations such as India and China lack of well-defined regulatory framework negatively impacts the market, irrespective of the presence of a large population.

The molecular diagnostic devices in the US are approved by Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH).These diagnostics devices are generally approved with an accompanying assay, in order to evaluate their safety and effectiveness or substantial equivalence with reference to the assays they run and the assay’s defined performance parameters.

However, the same instruments do not require FDA approval or clearance when used for basic scientific research-purposes.The European regulatory landscape has become more stringent and technically challenging for medical device companies.

The introduction of four different risk classes of diagnostic device, i.e. classes A-D. Class A refers to lowest risk tests and class D refers to highest risk test such as HIV testing, blood grouping, and prenatal testing. Most of the genetic testing is classed into class C. The products bearing a CE mark, European approved tests, are safe to use and are in full compliance.

In the US market, because of the changes in the rules and regulations, the products already in the market may also be required to go through Food and Drug Administration (FDA)’s pre-marketing approval process.For example, CLIA (Clinical Laboratory Improvement Amendments Act) in the US certifies the validity of a laboratory based tests but it does not regulate the clinical validity of molecular diagnostic tests.

This means that it does not control whether these results are clinically correct. This argument puts a restraint to the industry and opens an argument that FDA should play a greater role in overseeing laboratories.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on